Sparteine

Identification

Generic Name
Sparteine
DrugBank Accession Number
DB06727
Background

Sparteine is a plant alkaloid derived from Cytisus scoparius and Lupinus mutabilis which may chelate calcium and magnesium. It is a sodium channel blocker so it falls under the category of class 1a antiarrhythmic agents. Sparteine is not currently FDA approved for human use.

Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 234.387
Monoisotopic: 234.209598845
Chemical Formula
C15H26N2
Synonyms
  • (-)-sparteine
  • 6β,7α,9α,11α-pachycarpine
  • Esparteina
  • Lupinidine
  • Sparteina
  • Sparteine
  • Sparteinum

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe metabolism of Sparteine can be increased when combined with Abatacept.
AbirateroneThe metabolism of Sparteine can be decreased when combined with Abiraterone.
AcebutololAcebutolol may increase the arrhythmogenic activities of Sparteine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Sparteine.
AcetyldigitoxinAcetyldigitoxin may increase the arrhythmogenic activities of Sparteine.
AdalimumabThe metabolism of Sparteine can be increased when combined with Adalimumab.
AdenosineAdenosine may increase the arrhythmogenic activities of Sparteine.
AjmalineAjmaline may increase the arrhythmogenic activities of Sparteine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Sparteine.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Sparteine.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

ATC Codes
C01BA04 — Sparteine
Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
298897D62S
CAS number
90-39-1
InChI Key
SLRCCWJSBJZJBV-ZQDZILKHSA-N
InChI
InChI=1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2/t12-,13-,14-,15+/m0/s1
IUPAC Name
(1S,2R,9S,10S)-7,15-diazatetracyclo[7.7.1.0^{2,7}.0^{10,15}]heptadecane
SMILES
[H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2CCCC[C@]12[H]

References

Synthesis Reference

Bernd Hachmeister, "Process for the production of 17-hydroxysparteine by oxidation of sparteine with a permanganate." U.S. Patent US4237295, issued June, 1975.

US4237295
General References
Not Available
KEGG Drug
D01041
KEGG Compound
C10783
PubChem Compound
168213
PubChem Substance
99443273
ChemSpider
559096
ChEBI
28827
ChEMBL
CHEMBL1908847
ZINC
ZINC000001408502
PharmGKB
PA452610
Wikipedia
Sparteine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)30.5 °CPhysProp
boiling point (°C)325 °CPhysProp
water solubility3040 mg/L (at 22 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.931 mg/mLALOGPS
logP2.98ALOGPS
logP2.03ChemAxon
logS-2.4ALOGPS
pKa (Strongest Basic)9.16ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity71.82 m3·mol-1ChemAxon
Polarizability28.37 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9757
Blood Brain Barrier+0.9606
Caco-2 permeable+0.6725
P-glycoprotein substrateSubstrate0.55
P-glycoprotein inhibitor INon-inhibitor0.6379
P-glycoprotein inhibitor IINon-inhibitor0.8742
Renal organic cation transporterInhibitor0.7785
CYP450 2C9 substrateNon-substrate0.884
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6969
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9576
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9576
CYP450 3A4 inhibitorNon-inhibitor0.9518
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6629
Ames testNon AMES toxic0.6586
CarcinogenicityNon-carcinogens0.9538
BiodegradationNot ready biodegradable0.9974
Rat acute toxicity2.4193 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7831
hERG inhibition (predictor II)Non-inhibitor0.7092
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Halling J, Petersen MS, Damkier P, Nielsen F, Grandjean P, Weihe P, Lundgren S, Lundblad MS, Brosen K: Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol. 2005 Aug;61(7):491-7. doi: 10.1007/s00228-005-0938-1. Epub 2005 Jul 16. [Article]
  2. Damkier P, Hansen LL, Brosen K: Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol. 1999 Dec;48(6):829-38. [Article]
  3. Flockhart Table of Drug Interactions [Link]

Drug created on August 18, 2010 20:01 / Updated on February 21, 2021 18:52